The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
Open accessAbstract
Uric acid is the final oxidation product of purine metabolism in humans. Xanthine oxidoreductase (XOR) catalyzes oxidative hydroxylation of hypoxanthine to xanthine to uric acid, accompanying the production of reactive oxygen species (ROS). Uric acid usually forms ions and salts known as urates and acid urates in serum. Clinically, overproduction or under-excretion of uric acid results in the elevated level of serum uric acid (SUA), termed hyperuricemia, which has long been established as the major etiologic factor in gout. Accordingly, urate-lowering drugs such as allopurinol, an XOR-inhibitor, are extensively used for the treatment of gout. In recent years, the prevalence of hyperuricemia has significantly increased and more clinical investigations have confirmed that hyperuricemia is an independent risk factor for cardiovascular disease, hypertension, diabetes, and many other diseases. Urate-lowering therapy may also play a critical role in the management of these diseases. However, current XOR-inhibitor drugs such as allopurinol and febuxostat may have significant adverse effects. Therefore, there has been great effort to develop new XOR-inhibitor drugs with less or no toxicity for the long-term treatment or prevention of these hyperuricemia-related diseases. In this review, we discuss the mechanism of uric acid homeostasis and alterations, updated prevalence, therapeutic outcomes, and molecular pathophysiology of hyperuricemia-related diseases. We also summarize current discoveries in the development of new XOR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Ames, B. N., Cathcart, R., Schwiers, E., & Hochstein, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.6858 · Cited by 2,909
Radi, R., Beckman, J. S., Bush, K. M., & Freeman, B. A. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90224-7 · Cited by 2,194
Zhu, Y., Pandya, B. J., & Choi, H. K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30520 · Cited by 1,785
Molecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
Molecular identification of a renal urate–anion exchanger that regulates blood urate levels
Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Ho Cha, S., Hosoyamada, M., Takeda, M., Sekine, T., Igarashi, T., et al. (2002) · Nature · doi:10.1038/nature742 · Cited by 1,535
Molecular Regulation of Adipogenesis
Rosen, E. D., & Spiegelman, B. M. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.145 · Cited by 1,285
Pacher, P., Nivorozhkin, A., & Szabó, C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.6 · Cited by 1,218
Hyperuricemia induces endothelial dysfunction
Khosla, U. M., Zharikov, S., Finch, J. L., Nakagawa, T., Roncal, C., Mu, W., Krotova, K., Block, E. R., Prabhakar, S., & Johnson, R. J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00273.x · Cited by 1,199
Global epidemiology of gout: prevalence, incidence and risk factors
Kuo, C.-F., Grainge, M. J., Zhang, W., & Doherty, M. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.91 · Cited by 1,179
Mockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Sautin, Y. Y., Nakagawa, T., Zharikov, S., & Johnson, R. J. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00600.2006 · Cited by 787
Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases
Martyn, K. D., Frederick, L. M., von Loehneysen, K., Dinauer, M. C., & Knaus, U. G. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.023 · Cited by 783
Enroth, C., Eger, B. T., Okamoto, K., Nishino, T., Nishino, T., & Pai, E. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.20.10723 · Cited by 733
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N. (2008) · Arthritis Care & Research · doi:10.1002/art.24209 · Cited by 638
Liu, R., Han, C., Wu, D., Xia, X., Gu, J., Guan, H., Shan, Z., & Teng, W. (2015) · BioMed Research International · doi:10.1155/2015/762820 · Cited by 630
Uric acid and inflammatory markers
Ruggiero, C., Cherubini, A., Ble, A., Bos, A. J. G., Maggio, M., Dixit, V. D., Lauretani, F., Bandinelli, S., Senin, U., & Ferrucci, L. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi879 · Cited by 591
George, J., Carr, E., Davies, J., Belch, J. J. F., & Struthers, A. (2006) · Circulation · doi:10.1161/circulationaha.106.651117 · Cited by 569
Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-Sensitivity
Watanabe, S., Kang, D.-H., Feng, L., Nakagawa, T., Kanellis, J., Lan, H., Mazzali, M., & Johnson, R. J. (2002) · Hypertension · doi:10.1161/01.hyp.0000028589.66335.aa · Cited by 563
Xanthine oxidase and xanthine dehydrogenase
Hille, R., & Nishino, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.11.7649415 · Cited by 448
Uric acid in metabolic syndrome: From an innocent bystander to a central player
Kanbay, M., Jensen, T., Solak, Y., Le, M., Roncal-Jimenez, C., Rivard, C., Lanaspa, M. A., Nakagawa, T., & Johnson, R. J. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.11.026 · Cited by 419
Rao, G. N., Corson, M. A., & Berk, B. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)93017-6 · Cited by 391
Evolutionary history and metabolic insights of ancient mammalian uricases
Kratzer, J. T., Lanaspa, M. A., Murphy, M. N., Cicerchi, C., Graves, C. L., Tipton, P. A., Ortlund, E. A., Johnson, R. J., & Gaucher, E. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320393111 · Cited by 361
Weir, C. J., Muir, S. W., Walters, M. R., & Lees, K. R. (2003) · Stroke · doi:10.1161/01.str.0000081983.34771.d2 · Cited by 334
Yuan, H., Yu, C., Li, X., Sun, L., Zhu, X., Zhao, C., Zhang, Z., & Yang, Z. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2527 · Cited by 266
Li, M., Hu, X., Fan, Y., Li, K., Zhang, X., Hou, W., & Tang, Z. (2016) · Scientific Reports · doi:10.1038/srep19520 · Cited by 257
Battelli, M. G., Bolognesi, A., & Polito, L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.022 · Cited by 256
Molybdenum enzymes in higher organisms
Hille, R., Nishino, T., & Bittner, F. (2011) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2010.11.034 · Cited by 242
Gout therapeutics: new drugs for an old disease
Burns, C. M., & Wortmann, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60665-4 · Cited by 237
Choi, Y., Yoon, Y., Lee, K., Hien, T. T., Kang, K. W., Kim, K., Lee, J., Lee, M., Lee, S. M., Kang, D., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-247148 · Cited by 235
Regulation of Uric Acid Excretion by the Kidney
Lipkowitz, M. S. (2012) · Current Rheumatology Reports · doi:10.1007/s11926-012-0240-z · Cited by 221
Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk
Grassi, D., Ferri, L., Desideri, G., Di Giosia, P., Cheli, P., Del Pinto, R., Properzi, G., & Ferri, C. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319130011 · Cited by 208
Bagnati, M., Perugini, C., Cau, C., Bordone, R. P., Albano, E., & Bellomo, G. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3400143 · Cited by 190
The changing epidemiology of gout
Roddy, E., Zhang, W., & Doherty, M. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0556 · Cited by 190
Ogino, K., Kato, M., Furuse, Y., Kinugasa, Y., Ishida, K., Osaki, S., Kinugawa, T., Igawa, O., Hisatome, I., Shigemasa, C., et al. (2010) · Circulation: Heart Failure · doi:10.1161/circheartfailure.109.868604 · Cited by 190
Cicerchi, C., Li, N., Kratzer, J., Garcia, G., Roncal‐Jimenez, C. A., Tanabe, K., Hunter, B., Rivard, C. J., Sautin, Y. Y., Gaucher, E. A., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-243634 · Cited by 187
Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012
Ramasamy, S. N., Korb-Wells, C. S., Kannangara, D. R. W., Smith, M. W. H., Wang, N., Roberts, D. M., Graham, G. G., Williams, K. M., & Day, R. O. (2013) · Drug Safety · doi:10.1007/s40264-013-0084-0 · Cited by 182
Sundy, J. S., Becker, M. A., Baraf, H. S. B., Barkhuizen, A., Moreland, L. W., Huang, W., Waltrip, R. W., Maroli, A. N., Horowitz, Z., & Pegloticase Phase 2 Study Investigators (2008) · Arthritis & Rheumatism · doi:10.1002/art.23810 · Cited by 181
Braga, F., Pasqualetti, S., Ferraro, S., & Panteghini, M. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0523 · Cited by 181
Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects
Cherniakov, I., Domb, A. J., & Hoffman, A. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.999038 · Cited by 180
Xanthine Oxidoreductase Inhibition Causes Reverse Remodeling in Rats With Dilated Cardiomyopathy
Minhas, K. M., Saraiva, R. M., Schuleri, K. H., Lehrke, S., Zheng, M., Saliaris, A. P., Berry, C. E., Vandegaer, K. M., Li, D., & Hare, J. M. (2006) · Circulation Research · doi:10.1161/01.res.0000200181.59551.71 · Cited by 170
Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system
Pritsos, C. A. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00203-9 · Cited by 168
Acute adverse reactions attributed to allopurinol in hospitalised patients.
McInnes, G. T., Lawson, D. H., & Jick, H. (1981) · Annals of the Rheumatic Diseases · doi:10.1136/ard.40.3.245 · Cited by 160
LI, P., ZHANG, L., ZHANG, M., ZHOU, C., & LIN, N. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2491 · Cited by 159
Uric acid: an important antioxidant in acute ischaemic stroke
Waring, W. S. (2002) · QJM · doi:10.1093/qjmed/95.10.691 · Cited by 145
Song, Y. S., Kim, S., Sa, J.-H., Jin, C., Lim, C., & Park, E. (2003) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(03)00178-8 · Cited by 144
Inhibition by Uric Acid of Free Radicals that Damage Biological Molecules
Muraoka, S., & Miura, T. (2003) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.2003.pto930606.x · Cited by 139
Storhaug, H. M., Norvik, J. V., Toft, I., Eriksen, B. O., Løchen, M., Zykova, S. N., Solbu, M. D., White, S., Chadban, S. J., & Jenssen, T. G. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-115 · Cited by 137
Nitrosation of Uric Acid by Peroxynitrite
Skinner, K. A., White, C. R., Patel, R. P., Tan, S., Barnes, S., KIRK, M. C., Darley-Usmar, V. M., & Parks, D. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.38.24491 · Cited by 133
FYX-051: A Novel and Potent Hybrid-Type Inhibitor of Xanthine Oxidoreductase
Matsumoto, K., Okamoto, K., Ashizawa, N., & Nishino, T. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174540 · Cited by 130
Zhang, Y., Yamamoto, T., Hisatome, I., Li, Y., Cheng, W., Sun, N., Cai, B., Huang, T., Zhu, Y., Li, Z., et al. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.04.027 · Cited by 128
Chohan, S. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110092 · Cited by 126
Cellular expression of xanthine oxidoreductase protein in normal human tissues.
Linder, N., Rapola, J., & Raivio, K. O. (1999) · PubMed · Cited by 125
Allopurinol and Cardiovascular Outcomes in Adults With Hypertension
MacIsaac, R. L., Salatzki, J., Higgins, P., Walters, M. R., Padmanabhan, S., Dominiczak, A. F., Touyz, R. M., & Dawson, J. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06344 · Cited by 124
Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle
Hellsten, Y. (1993) · Histochemistry and Cell Biology · doi:10.1007/bf00269094 · Cited by 123
Radí, R., Rubbo, H., Bush, K., & Freeman, B. Α. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.9844 · Cited by 119
Okamoto, K., Eger, B. T., Nishino, T., PAI, E. F., & Nishino, T. (2008) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770802146577 · Cited by 118
Urate‐Lowering Therapy for Gout: Focus on Febuxostat
Love, B. L., Barrons, R., Veverka, A., & Snider, K. M. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.594 · Cited by 112
Impact of allopurinol on risk of myocardial infarction
Grimaldi‐Bensouda, L., Alpérovitch, A., Aubrun, E., Danchin, N., Rossignol, M., Abenhaim, L., & Richette, P. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202972 · Cited by 112
Similar Functions of Uric Acid and Ascorbate in Man ?
Proctor, P. H. (1970) · Nature · doi:10.1038/228868a0 · Cited by 111
Factors affecting urate solubility in vitro.
Kippen, I., Klinenberg, J. R., Weinberger, A., & Wilcox, W. R. (1974) · Annals of the Rheumatic Diseases · doi:10.1136/ard.33.4.313 · Cited by 109
Uric acid and cardiovascular disease risk reclassification: Findings from NHANES III
ZALAWADIYA, S. K., Veeranna, V., Mallikethi‐Reddy, S., Bavishi, C., Lunagaria, A., Kottam, A. R., & Afonso, L. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487313519346 · Cited by 89
The epidemiology of hyperuricaemia and gout in Taiwan aborigines
Chou, C., & Lai, J. S. (1998) · Rheumatology · doi:10.1093/rheumatology/37.3.258 · Cited by 88
Chen, S., Zhang, T., Wang, J., Wang, F., Niu, H., Wu, C., & Wang, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.056 · Cited by 87
Oral delivery of anticancer drugs III: formulation using drug delivery systems
Mazzaferro, S., Bouchemal, K., & Ponchel, G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.007 · Cited by 87
Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors
Song, J. U., Choi, S. P., Kim, T. H., Jung, C.-K., Lee, J., Jung, S., & Kim, G. T. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.055 · Cited by 85
Association between serum uric acid and nonalcoholic fatty liver disease in the US population
Shih, M., Lazo, M., Liu, S., Bonekamp, S., Hernáez, R., & Clark, J. M. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.11.014 · Cited by 83
Insights into the inhibition of xanthine oxidase by curcumin
Shen, L., & Ji, H. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.076 · Cited by 83
Lü, J.-M., Yao, Q. C., & Chen, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.011 · Cited by 81
Self-citationAllopurinol initiation and all-cause mortality in the general population
Dubreuil, M., Zhu, Y., Zhang, Y., Seeger, J. D., Lu, N., Rho, Y. H., & Choi, H. K. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205269 · Cited by 80
Katsiki, N., Karagiannis, A. I., Athyros, V. G., & Mikhailidis, D. P. (2012) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283595adc · Cited by 78
Lin, M. S., Dai, Y.-S., Pwu, R., Chen, Y., & Chang, N. C. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2005.00790.x · Cited by 71
Bardin, T., Chalès, G., Pascart, T., Flipo, R.-M., Ea, H., Roujeau, J., Delayen, A., & Clerson, P. (2015) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.07.011 · Cited by 68
Borghi, C., & Desideri, G. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06531 · Cited by 67
N-(1,3-Diaryl-3-oxopropyl)amides as a new template for xanthine oxidase inhibitors
Nepali, K., Agarwal, A., Sapra, S., Mittal, V., Kumar, R., Banerjee, U. C., Gupta, M., Satti, N. K., Suri, O. P., & Dhar, K. L. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.039 · Cited by 64
Hypochlorite induces lipid peroxidation in blood lipoproteins and phospholipid liposomes
Panasenko, O. M., Evgina, S. A., Driomina, E. S., Sharov, V. S., Сергиенко, В. И., & IuA, V. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)00211-2 · Cited by 63
XDH gene mutation is the underlying cause of classical xanthinuria: A second report
Levartovsky, D., Lagziel, A., Sperling, O., Liberman, U. A., Yaron, M., Hosoya, T., Ichida, K., & Peretz, H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00082.x · Cited by 58
A comprehensive review on bioactive fused heterocycles as purine-utilizing enzymes inhibitors
Chauhan, M., & Kumar, R. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1295-3 · Cited by 55
Iron regulates xanthine oxidase activity in the lung
Ghio, A. J., Kennedy, T. P., Stonehuerner, J. G., Carter, J. D., Skinner, K. A., Parks, D. A., & Hoidal, J. R. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00413.2000 · Cited by 55
Kumar, D., Kaur, G., Negi, A., Kumar, S., Singh, S., & Kumar, R. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.08.007 · Cited by 53
Sharma, S., Sharma, K., Ojha, R., Kumar, D., Singh, G., Nepali, K., & Bedi, P. M. S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.031 · Cited by 51
Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?
Lee, M. H., STOCKER, S. L., Anderson, J., et al. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02567.x · Cited by 48
Hosoya, T., Sasaki, T., Hashimoto, H., Sakamoto, R., & Ohashi, T. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12392 · Cited by 47
Deciphering the inhibitory mechanism of genistein on xanthine oxidase in vitro
Lin, S., Zhang, G., Pan, J., & Gong, D. (2015) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2015.10.022 · Cited by 44
Febuxostat‐induced acute liver injury
Bohm, M., Vuppalanchi, R., Chalasani, N., & The Drug‐Induced Liver Injury Network (DILIN) (2015) · Hepatology · doi:10.1002/hep.28403 · Cited by 44
Abeles, A. M. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.111161 · Cited by 44
for the Community Health and Academic Medicine Partnership Project, Russell, B. E., Gurrola, E., Ndumele, C. D., Landon, B. E., O’Malley, A. J., Keegan, T., Ayanian, J. Z., & Hicks, L. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1278-0 · Cited by 32
Allopurinol: novel indications in cardiovascular disease
Struthers, A. D., & Shearer, F. A. (2012) · Heart · doi:10.1136/heartjnl-2012-302249 · Cited by 32
9-Benzoyl 9-deazaguanines as potent xanthine oxidase inhibitors
Rodrigues, M. V. N., Barbosa, A. F., da Silva, J. F., dos Santos, D. A., Vanzolini, K. L., de Moraes, M. C., Corrêa, A. G., & Cass, Q. B. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.12.006 · Cited by 32
Chen, A. Y., Lü, J.-M., Yao, Q. C., & Chen, C. (2016) · Medical Science Monitor · doi:10.12659/msm.896462 · Cited by 32
Self-citationCalogiuri, G., Nettis, E., Leo, E. D., Foti, C., Ferrannini, A., & Butani, L. (2013) · Inflammation & Allergy - Drug Targets · doi:10.2174/1871528111312010004 · Cited by 29
Zhang, J., Shuai, X., Li, J., Xiang, N., Gong, T., & Zhang, Z. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12492 · Cited by 26
Kang, Y., Kim, M. J., Jang, H. N., Bae, E., Yun, S.-E., Cho, H. S., Chang, S., & Park, D. J. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12144 · Cited by 21
Sun, Z., Zhou, X.-J., Zhu, M., Ding, W.-Z., Li, Z., & Zhu, H. (2015) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c15-00282 · Cited by 13
Antihyperuricemic effects of thiadiazolopyrimidin-5-one analogues in oxonate treated rats
Sathisha, K., Gopal, S., & Rangappa, K. S. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.039 · Cited by 12
Kim, H. O., Ihm, C., Jeong, K. H., Kang, H. J., Kim, J., Lim, H. S., Kim, J. S., & Lee, T. W. (2015) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2015.13.2.52 · Cited by 12
(2014) · PubMed
Cited by
Uric acid and cardiovascular disease
Ndrepepa, G. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.046 · Cited by 498
Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis
Poznyak, A. V., Nikiforov, N. G., Markin, A. M., Kashirskikh, D. A., Myasoedova, V. A., Gerasimova, E. V., & Orekhov, A. N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.613780 · Cited by 370
Metadata
- Authors
- Chen, C., Lü, J.-M., & Yao, Q.
- Venue
- Medical Science Monitor
- Published
- 2016-07-17
- Volume
- 22
- Pages
- 2501-2512
- ISSN
- 1234-1010 (ISSN-L)
- 1643-3750
- OpenAlex
- W2516136724
- Cited by
- 302
- References
- 98
- FWCI
- 16.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.